rh 1

RH1 (NSC 697726) is a bioreductive anticancer compound that exhibits dose-dependent biphasic effects in vitro, inducing apoptosis at higher doses and senescence at lower doses.

[D-Leu6, Val7]-LH-RH (1-9) Ethyl Amide is an LH-RH peptide analogue.

RH-5849 (1,2-Dibenzoyl-1-Tert-Butylhydrazine) is a novel Insect growth regulator that can be used as a potential insecticide to control olive fruit fly.

Ginsenoside Rh1 (Sanchinoside B2) , one of the main constituents of Panax ginseng, exhibits anti-inflammatory effect.

[D-Glp1,D-Phe2,D-Trp3,6]-LH-RH, a luteinizing hormone-releasing hormone (LHRH) analogue, acts as a gonadotropin-releasing hormone (GnRH) receptor antagonist [1].

(20R)-Ginsenoside Rh1 (20(R)-Ginsenoside Rh1) can inhibit the thrombin-induced conversion of fibrinogen to fibrin.

Sarpogrelate hydrochloride (MCI-9042) , a selective 5-HT2 antagonist, has been widely used as an anti-platelet agent for the treatment of PAD. Target: 5-HT2 Recepter Sarpogrelate is a drug which acts as an antagonist at the 5HT2A and 5-HT2B receptors. Sarpogrelate hydrochloride was shown to have the same affinity as ritanserin for 5-HT2A receptors, with a Ki value of 8.39 nM. Sarpogrelate hydrochloride lacked prominent 5-HT1-like, 5-HT3, beta, H1, H2 and M3 antagonist activity and weakly blocked alpha 1-adrenoceptors (pKB = 6.30). (S)-M-1 showed weak affinity for 5-HT1-like receptors (pKB = 6.30), alpha 1- (pKB = 6.80) and beta- (pKB = 6.54) adrenoceptors, while (R)-M-1 was a weak antagonist at histamine H1 receptors (pKB = 6.49). After 12 weeks of sarpogrelate administration, FBF and LBF responses during RH showed significant increases from 13.2 +/- 1.7 to 18.1 +/- 2.2 mL/min per 100 mL tissue (P < 0.01) and from 8.2 +/- 0.9 to 14.2 +/- 2.1 mL/min per 100 mL tissue (P < 0.05), respectively. Sarpogrelate hydrochloride -induced augmentation of FBF and LBF responses to RH was maintained at 24 weeks. Long-term oral administration of sarpogrelate improves vascular function in patients with PAD.

1-Caffeoylquinic acid is an important intermediate in lignin biosynthesis. 1-Caffeoylquinic acid has anti-influenza, and antioxidant activities, it also slows the release of glucose into the bloodstream after a meal.

Renin inhibitor-1 (compound 26) is a potent and orally active renin inhibitor with IC50 values of 0.9 nM against rh-renin and 1.8 nM against hPRA, potentially useful for renal disease treatment.

Gonadotropin-Releasing Hormone-Associated Peptide (GAP) (1-24), human, also known as hGAP-1-24, is the 1-24 fragment of the human GAP, which is connected to the luteinizing hormone-releasing hormone (LH-RH) through a 3 amino acid processing site [1].

LH-RH (4-10), a heptapeptide, represents one of the primary degradation products of luteinising-hormone releasing hormone (LHRH), occurring through the pathways of the pituitary and hypothalamus. It is produced in macrophages and type II pneumocytes [1].

[D-Lys6]-LH-RH, a Luteinizing-hormone-releasing hormone (LHRH) analogue, serves as a GnRH receptor agonist [1].

[D-Phe2,D-Ala6]-LH-RH is a potent luteinizing hormone-releasing hormone (LH-RH) antagonist, exhibiting significant activity against LH FSH-RH and possessing the ability to inhibit ovulation [1].

[Lys8] LH-RH, an analogue of LH-RH, effectively stimulates the release of luteinizing hormone (LH) and follicle-stimulating hormone (FSH) [1].

PXS-4787 is a potent and selective inhibitor of lysyl oxidase (LOX) with broad-spectrum activity. It effectively suppresses lysyl oxidase activity by acting on its mechanisms. The compound displays inhibitory effects with IC50 values of 2 μM (Bovine LOX), 3.2 μM (rh LOXL1), 0.6 μM (rh LOXL2), 1.4 μM (rh LOXL3), and 0.2 μM (rh LOXL4), respectively [1].

Gonadotropin-Releasing Hormone-Associated Peptide (GAP) (25-53), Human, also known as hGAP-25-53, is a fragment of the human gonadotropin-releasing hormone-associated peptide that serves as an immunogen for producing antiseras such as MC-1, MC-2, and MC-3. This peptide is connected to the luteinizing hormone-releasing hormone (LH-RH) sequence through a 3 amino acid processing site [1].

Zoxamide (RH-7281) is an oomycete-specific fungicide that obstructs nuclear division in Phytophthora capsici germlings and disrupts the microtubule cytoskeleton [1] [2].

Sarpogrelate-d3 HCl is a deuterated compound of Sarpogrelate HCl. Sarpogrelate HCl has a CAS number of 135159-51-2. Sarpogrelate(MCI-9042) hydrochloride, a selective 5-HT2 antagonist, has been widely used as an anti-platelet agent for the treatment of PAD. Target: 5-HT2 Recepter Sarpogrelate is a drug which acts as an antagonist at the 5HT2A and 5-HT2B receptors. Sarpogrelate was shown to have the same affinity as ritanserin for 5-HT2A receptors, with a Ki value of 8.39 nM. Sarpogrelate lacked prominent 5-HT1-like, 5-HT3, beta, H1, H2 and M3 antagonist activity and weakly blocked alpha 1-adrenoceptors (pKB = 6.30). (S)-M-1 showed weak affinity for 5-HT1-like receptors (pKB = 6.30), alpha 1- (pKB = 6.80) and beta- (pKB = 6.54) adrenoceptors, while (R)-M-1 was a weak antagonist at histamine H1 receptors (pKB = 6.49). After 12 weeks of sarpogrelate administration, FBF and LBF responses during RH showed significant increases from 13.2 +/- 1.7 to 18.1 +/- 2.2 mL/min per 100 mL tissue (P < 0.01) and from 8.2 +/- 0.9 to 14.2 +/- 2.1 mL/min per 100 mL tissue (P < 0.05), respectively. Sarpogrelate-induced augmentation of FBF and LBF responses to RH was maintained at 24 weeks. Long-term oral administration of sarpogrelate improves vascular function in patients with PAD.

LH-RH II (chicken), a structural variant of mammalian luteinizing hormone-releasing hormone (LHRH) found in the hypothalamus of the domestic hen, exists as one of two forms of LHRH that enhance gonadotropin release in domestic chickens [1] [2].

[D-Ala6]-LH-RH, a Luteinizing-hormone-releasing hormone (LHRH) analogue, functions as a gonadotropin-releasing hormone (GnRH) receptor agonist [1].

Lamprey LH-RH I, a gonadotropin-releasing hormone, effectively increases plasma steroid levels and induces ovulation in lampreys, yet demonstrates no biological activity in other animal models [1].

Sarpogrelate (MCI-9042) is a new, orally active, specific 5-HT2 receptor antagonist that increases platelet aggregation, has a haemostatic effect, and can be used in the study of Berghett's disease.